Skip to content

Clinical trials

Melanoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Melanoma Clear all

3,195 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200040
200141
200242
200353
200478
200588
200688
200783
200894
200991
201097
2011103
2012104
2013136
2014124
2015155
2016146
2017136
2018158
2019150
2020151
2021183
2022175
2023138
2024121
2025138
2026108

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed1,516
Terminated503
Recruiting390
Unknown status307
Active, not recruiting242
Withdrawn110
Not yet recruiting78
Suspended19
No longer available16
Enrolling by invitation9
Available5

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)206
M.D. Anderson Cancer Center101
Bristol-Myers Squibb90
Memorial Sloan Kettering Cancer Center63
Hoffmann-La Roche45
Novartis Pharmaceuticals45
Mayo Clinic41
Pfizer38
H. Lee Moffitt Cancer Center and Research Institute37
Merck Sharp & Dohme LLC35

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Melanoma3,195
Carcinoma, Non-Small-Cell Lung404
Neoplasms308
Carcinoma, Renal Cell290
Breast Neoplasms287
Neoplasm Metastasis272
Colorectal Neoplasms222
Skin Neoplasms209
Lung Neoplasms208
Ovarian Neoplasms188

Trials

Showing 76 to 100 of 3,195. Each trial links to its page on Pharma Observatory.

3,095 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.